Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Sangamo Therapeutics Inc chart...

About the Company

for sangamo therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. our scientists are leaders in the discovery, research and development of technologies enabling gene-based therapeutic development. currently we are conducting clinical trials, including the first ever in vivo human genome editing studies. to learn more about sangamo, visit the our website at www.sangamo.com.

CEO

Alexander Macrae

Exchange

NASDAQ

Website

https://www.sangamo.com/

$565M

Total Revenue

520

Employees

$139M

Market Capitalization

-0.50

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SGMO News

Q4 2023 Sangamo Therapeutics Inc Earnings Call

4d ago, source:

Amy Pooler; Head of Research; Sangamo Therapeutics Inc Nathalie Dubois- Stringfellow; Senior Vice President, Chief Development Officer; Sangamo Therapeutics Inc Luis Santos; Analyst; H.C. Wainwritght ...

Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Tr…

5d ago, source: Business Wire

SANGAMO ANNOUNCES DATA FROM PROPRIETARY NEUROTROPIC AAV CAPSID DEMONSTRATING INDUSTRY-LEADING BLOOD-BRAIN BARRIER PENETRATION ...

4 Analysts Assess Sangamo Therapeutics: What You Need To Know

5d ago, source: Business Insider

Delving into Sangamo Therapeutics's Background Sangamo Therapeutics Inc is a clinical-stage biotechnology company that translates ground-breaking science into genomic therapies transforming patients' ...

Sangamo Therapeutics files patent for zinc finger fusion protein to treat neurodegenerative diseases

6d ago, source: Pharmaceutical Technology

Discover Sangamo Therapeutics' groundbreaking patent for zinc finger fusion proteins targeting alpha-synuclein gene to combat neurodegenerative diseases like Parkinson's and Alzheimer's. Learn about ...

Sangamo: Q4 Earnings Snapshot

5d ago, source:

BRISBANE, Calif. — BRISBANE, Calif. — Sangamo Therapeutics Inc. (SGMO) on Wednesday reported a loss of $60.3 million in its fourth quarter. On a per-share basis, the Brisbane, California-based company ...

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

5d ago, source: Business Wire

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results ...

Sangamo Biosciences Earns Buy Rating on Breakthrough Brain-Targeting Gene Therapy Capsid and Strategic Advancements

4d ago, source:

TD Cowen analyst Ritu Baral has maintained their bullish stance on SGMO stock, giving a Buy rating yesterday. Ritu Baral has given his Buy ...

With 55% ownership of the shares, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is heavily dominated by institutional owners

1mon ago, source: Yahoo Finance

This can be negative in some circumstances. Our information suggests that Sangamo Therapeutics, Inc. insiders own under 1% of ...

Chutes & Ladders—Voyager plucks another Biogen exec for top post

3d ago, source: FierceBiotech

Voyager Therapeutics plucks another Biogen exec, naming Ferguson as new CMO. Pfizer names CSO for anti-infectives research ...

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

10d ago, source:

Voyager Therapeutics investors need to be patient as the biotech targets hard to treat Alzheimer's and Parkinson's. Read why ...

Voyager Therapeutics, Inc.: Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer

5d ago, source:

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...